Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Celgene Corp.
Focalin LA pivotal clinical trial initiated in adults with ADD/ADHD
July 30th, 2003
Celgene Corp. (CELG) announced that a pivotal clinical trial of Focalin LA (dexmethylphenidate hydrochloride extended-release capsules) in adults with attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD) has been initiated. Novartis Pharmaceuticals Corp. has marketing rights to Focalin LA in the United States and will conduct the multicenter, controlled, pivotal trial to evaluate the safety and efficacy of Focalin LA administered once daily in adult patients with ADD/ADHD. "We are very pleased that our partner Novartis has initiated this pivotal trial to evaluate Focalin LA, the long-acting formulation of Focalin, as a...
Source: Biotech Week (2003-07-30)
|
